Characteristic | Children (age < 18 y) (n = 121) | Adults (age ≥ 18 y) (n = 148) | Total (N = 269) |
---|---|---|---|
Age at enrollment,a y | n = 121 | n = 148 | n = 269 |
Mean (SD) | 5.7 (4.7) | 48.8 (15.4) | 29.4 (24.5) |
Median (min, max) | 4.3 (−0.01, 17.3) | 51.4 (18.5, 78.9) | 26.0 (−0.01, 78.9) |
Sex, n (%) | n = 121 | n = 148 | n = 269 |
Female | 74 (61.2) | 108 (73.0) | 182 (67.7) |
Race,b n (%) | n = 111 | n = 140 | n = 251 |
White | 64 (57.7) | 126 (90.0) | 190 (75.7) |
Asian | 35 (31.5) | 3 (2.1) | 38 (15.1) |
American Indian or Alaska Native | 0 | 2 (1.4) | 2 (0.8) |
Native Hawaiian or other Pacific Islander | 0 | 1 (0.7) | 1 (0.4) |
Other/multiple | 5 (4.5) | 4 (2.9) | 9 (3.6) |
Not reported | 7 (6.3) | 4 (2.9) | 11 (4.4) |
Ethnicity,b n (%) | n = 121 | n = 147 | n = 268 |
Not Hispanic or Latino | 103 (85.1) | 116 (78.9) | 219 (81.7) |
Hispanic or Latino | 4 (3.3) | 18 (12.2) | 22 (8.2) |
Not reported | 14 (11.6) | 13 (8.8) | 27 (10.1) |
Family history of HPP, n (%) | n = 117 | n = 135 | n = 252 |
Yes | 50 (42.7) | 66 (48.9) | 116 (46.0) |
No | 61 (52.1) | 54 (40.0) | 115 (45.6) |
Not reported | 6 (5.1) | 15 (11.1) | 21 (8.3) |
Treated with asfotase alfa at enrollment, n (%) | n = 121 | n = 148 | n = 269 |
Yes | 45 (37.2) | 26 (17.6) | 71 (26.4) |